Orion Oyj B

Tenax Therapeutics’ Phase 3 LEVEL trial fails to hit primary endpoints but shows promise in a high‑burden subgroup—strategic implications for regulatory, partnership, and market‑access moves in the HFpEF‑PH space.

Orion Oyj’s Q1 results show solid growth, tighter 2026 guidance and a promising pan‑TEAD inhibitor basket trial, signaling a bold push in oncology.

Orion Oyj revamps its long‑term incentive plan, aligning executive rewards with 2026 growth goals while hinting at a higher dividend, all driven by Nubeqa’s strong sales and solid EBITDA margins.

Orion’s Nubeqa sales projected to top €1 billion, driven by solid phase III data, EU approvals and high‑margin oncology revenue growth.